Literature DB >> 23809783

Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates.

J Vanderpas1, P Bontems2, V Y Miendje Deyi3, S Cadranel2.   

Abstract

Helicobacter pylori culture on gastric biopsy was performed on 4964 subjects aged <18 years from 1988 to 2007 at a central laboratory in Brussels. The total number of biopsies increased markedly from 941 in 1988-1993 to 1608 in 2004-2007. Biopsies were repeated at least once for 922 subjects (603 initially negative and 319 initially positive for H. pylori). Persistence rate of H. pylori at 1 year after initial positive biopsy was greater in the 1998-2007 cohort than in the 1988-1997 cohort (72.7% vs. 45.8%, P = 0.002), suggesting a tailored selection of candidates for biopsy with non-invasive tests (13C urea breath test). Of 68 subjects initially positive and re-examined subsequently after a documented cure, re-infection/relapse rate was 48.6% within 5 years post-elimination of H. pylori. Acquisition rate over 10 years follow-up in the initially negative cohort (603 patients) was 38.7% (re-infection/relapse vs. acquisition: P < 0.001). Multivariate analysis showed a fourfold greater risk of H. pylori acquisition in children of non-European origin vs. European origin (P < 0.001). Clarithromycin and metronidazole susceptibility were determined in 226 and 223 paired positive cultures in cases of re-infection/relapse or persistence. An initial non-susceptibility profile was highly predictive of a subsequent non-susceptibility profile, and the non-susceptible proportion increased markedly from 13.3% to 21.2% for clarithromycin (P < 0.001) and from 27.3% to 35.0% for metronidazole (P = 0.014), with no difference regarding European or non-European origin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23809783      PMCID: PMC9151151          DOI: 10.1017/S0950268813001428

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  18 in total

Review 1.  Clinical practice. Helicobacter pylori infection.

Authors:  Kenneth E L McColl
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Mass eradication of Helicobacter pylori: feasible and advisable?

Authors:  Luiz Edmundo Mazzoleni; Carlos Fernando Francesconi; Guilherme Becker Sander
Journal:  Lancet       Date:  2011-07-21       Impact factor: 79.321

3.  Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy.

Authors:  S Cadranel; P Bontemps; S Van Biervliet; P Alliet; D Lauvau; G Vandenhoven; Y Vandenplas
Journal:  Acta Paediatr       Date:  2007-01       Impact factor: 2.299

4.  Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Authors:  V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

5.  Results from the pediatric European register for treatment of Helicobacter pylori (PERTH).

Authors:  Giuseppina Oderda; Peter Shcherbakov; Patrick Bontems; Pedro Urruzuno; Claudio Romano; Frederic Gottrand; M Jose Martinez Gómez; Alberto Ravelli; Paolo Gandullia; Elefteria Roma; Sami Cadranel; Costantino De Giacomo; Roberto Berni Canani; Vincenzo Rutigliano; Ender Pehlivanoglu; Nicolas Kalach; Paola Roggero; Danuta Celinska-Cedro; Brendan Drumm; Thomas Casswall; Marja Ashorn; Sanda Nousia Arvanitakis
Journal:  Helicobacter       Date:  2007-04       Impact factor: 5.753

6.  Helicobacter pylori reinfection in Brazilian patients with peptic ulcer disease: a 5-year follow-up.

Authors:  Fernando M Silva; Tomas Navarro-Rodriguez; Ricardo C Barbuti; Rejane Mattar; Claudio L Hashimoto; Jaime N Eisig
Journal:  Helicobacter       Date:  2010-02       Impact factor: 5.753

Review 7.  Helicobacter pylori persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection.

Authors:  Diana A Moya; Karen D Crissinger
Journal:  Curr Gastroenterol Rep       Date:  2012-06

8.  Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication--a 7-year follow-up study.

Authors:  Giovanni Maconi; Massimo Sainaghi; Mirko Molteni; Matteo Bosani; Silvano Gallus; Giorgio Ricci; Vittorio Alvisi; Gabriele Bianchi Porro
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-04       Impact factor: 2.566

9.  Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.

Authors:  E Hentschel; G Brandstätter; B Dragosics; A M Hirschl; H Nemec; K Schütze; M Taufer; H Wurzer
Journal:  N Engl J Med       Date:  1993-02-04       Impact factor: 91.245

10.  Detection of Helicobacter pylori infection in children with a standardized and simplified 13C-urea breath test.

Authors:  S Cadranel; L Corvaglia; P Bontems; C Deprez; Y Glupczynski; A Van Riet; E Keppens
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-09       Impact factor: 2.839

View more
  4 in total

1.  Isolation and characterization of bacteria associated with the rhizosphere of halophytes (Salsola stocksii and Atriplex amnicola) for production of hydrolytic enzymes.

Authors:  Salma Mukhtar; Samina Mehnaz; Muhammad Sajjad Mirza; Kauser Abdulla Malik
Journal:  Braz J Microbiol       Date:  2019-01-08       Impact factor: 2.476

Review 2.  Prevention of Helicobacter pylori infection in childhood.

Authors:  Oya Yucel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Helicobacter pylori Infection in Children: a Comprehensive Review.

Authors:  Sanaz Mehrabani
Journal:  Maedica (Buchar)       Date:  2019-09

4.  The effect of virulence genotypes of Helicobacter pylori on eradication therapy in children.

Authors:  Shuang-Hong Zhang; Xuan Zhu; Bi-Min Li; Hong Li
Journal:  Saudi J Gastroenterol       Date:  2018 Jul-Aug       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.